tabalumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470476568

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = BAFF

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1143503-67-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = PQP8VH3MJW

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG = D10083

| C=6518 | H=10008 | N=1724 | O=2032 | S=38

}}

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}{{cite web | title = BAFF Antibody: Tabalumab, LY2127399 | publisher = Lilly USA, LLC | url = http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx | archive-url = https://web.archive.org/web/20130812045007/http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx | archive-date = 12 August 2013 }} Tabalumab was developed by Eli Lilly and Company.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.{{Cite web|url=http://lilly.mediaroom.com/index.php?s=9042&item=136985|title = Press Release Archive - Press Release Archives}} In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.{{Cite web|url=http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/|title=Lilly Halts Tabalumab Development for Lupus|date=2 October 2014}}